What is the Share Price of Windlas Biotech Ltd?
- Answer Field
-
The share price of Windlas Biotech Ltd for NSE is ₹ 965.5 and for BSE is ₹ 960.6.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, WINDLAS BIOTECH LIMITED share price is currently at ₹ 965.5, which is down by ₹ -9.40 from its previous closing. Today, the stock has fluctuated between ₹ 958.10 and ₹ 990.50. Over the past year, WINDLAS BIOTECH LIMITED has achieved a return of 77.62 %. In the last month alone, the return has been -4.03 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 195.02 |
Operating Expense | 178.78 |
Net Profit | 15.23 |
Net Profit Margin (%) | 7.80 |
Earnings Per Share (EPS) | 7.29 |
EBITDA | 28.37 |
Effective Tax Rate (%) | 23.73 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 37.10 | 19.95 | 2.02 | 284.31 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 122.65 | 16.07 | 1.27 | 1292.37 | 92.25 / 184.95 |
CIPLA LTD | 1541.00 | 24.94 | 4.38 | 124457.39 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 272.25 | 22.56 | 2.76 | 801.26 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 37.10 | 22.35 | 6.30 | 284.31 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 679.10 | 39.81 | 6.59 | 1963.32 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8795.90 | 131.18 | 32.36 | 21989.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 122.65 | 15.93 | 1.26 | 1292.37 | 92.25 / 184.95 |
Windlas Biotech Limited (formerly known as Windlas Biotech Private Limited) was incorporated in 2001. The Company converted
from a Private Limited Company to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'. A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun.
The Company is engaged in manufacturing and trading of pharmaceutical products. TheIR manufacturing facilities are located at Dehradun in Uttarakhand. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semi-urban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports.
The Company commenced operations at Dehradun Plant -IV in 2010. It provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries.
The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and low-solubility products.
Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible.
In 2020, the Company acquired the erstwhile associate -Windlas Healthcare.
To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.
In August 2021, the Company made an Initial Public Offer of 8,729,023 Equity Shares by raising capital from public aggregating to Rs 401.53 Crore, comprising a Fresh Issue of 3,586,956 Equity Shares aggregating to Rs 165 Crore and an Offer for Sale of 5,142,067 Equity Shares
aggregating to Rs 236.53 Crore.
The share price of Windlas Biotech Ltd for NSE is ₹ 965.5 and for BSE is ₹ 960.6.
The market cap of Windlas Biotech Ltd for NSE is ₹ 20,08.10 Cr. and for BSE is ₹ 19,97.91 Cr. as of now.
The 52 Week High and Low of Windlas Biotech Ltd for NSE is ₹ 1198.25 and ₹ 495.65 and for BSE is ₹ 1197.00 and ₹ 494.70.
You can trade in Windlas Biotech Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 77.62%.
Windlas Biotech Ltd share price is for NSE ₹ 965.5 & for BSE ₹ 960.6 as on Apr 30 2025 03:30 PM.
The market cap of Windlas Biotech Ltd for NSE ₹ 20,08.10 & for BSE ₹ 19,97.91 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Windlas Biotech Ltd share is 33.21.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Windlas Biotech Ltd share is 225.62.
You can trade in Windlas Biotech Ltd shares with Bajaj Broking by opening a demat account.
To buy Windlas Biotech Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Windlas Biotech Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found